Scientists weaponize herpes virus to attack deadly brain cancer
NCT ID NCT02062827
Summary
This early-stage study is testing a modified herpes virus (M032) designed to infect and kill brain tumor cells while boosting the immune system. The trial aims to find the safest dose for 29 adults with recurrent glioblastoma or similar aggressive brain cancers who have few treatment options. The virus is injected directly into the tumor and is engineered to target cancer cells while sparing healthy tissue.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA MULTIFORME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
Conditions
Explore the condition pages connected to this study.